Analysts predict that TherapeuticsMD, Inc. (NASDAQ:TXMD) will post $4.69 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for TherapeuticsMD’s earnings, with estimates ranging from $4.00 million to $5.50 million. TherapeuticsMD posted sales of $4.49 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.5%. The business is scheduled to issue its next earnings results on Thursday, February 22nd.

On average, analysts expect that TherapeuticsMD will report full year sales of $4.69 million for the current financial year, with estimates ranging from $16.70 million to $18.15 million. For the next fiscal year, analysts forecast that the company will report sales of $44.81 million per share, with estimates ranging from $32.64 million to $74.22 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The business had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business’s revenue for the quarter was down 19.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.13) EPS.

A number of research analysts recently issued reports on TXMD shares. Cowen reissued an “outperform” rating and set a $16.00 price target (up from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. Deutsche Bank restated a “buy” rating and set a $10.00 target price on shares of TherapeuticsMD in a research report on Wednesday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $33.00 price target on shares of TherapeuticsMD in a research report on Tuesday, August 15th. Morgan Stanley started coverage on shares of TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price on the stock. Finally, BidaskClub raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $14.50.

A number of institutional investors have recently added to or reduced their stakes in TXMD. Managed Account Services Inc. raised its position in TherapeuticsMD by 5.5% during the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank grew its position in shares of TherapeuticsMD by 7.2% in the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after acquiring an additional 1,322 shares in the last quarter. Principal Financial Group Inc. boosted its position in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares during the period. Traynor Capital Management Inc. grew its stake in TherapeuticsMD by 14.0% in the second quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after purchasing an additional 2,799 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in TherapeuticsMD in the second quarter valued at about $157,000. 73.72% of the stock is currently owned by institutional investors.

Shares of TherapeuticsMD (NASDAQ TXMD) traded up $0.23 during midday trading on Friday, reaching $6.30. 5,399,600 shares of the company traded hands, compared to its average volume of 2,903,786. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD, Inc. (TXMD) Expected to Announce Quarterly Sales of $4.69 Million” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/01/therapeuticsmd-inc-txmd-expected-to-announce-quarterly-sales-of-4-69-million-3.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.